Washington, DC (February 24, 2016) – The National Health Council (NHC) publicly thanked the Members of the U.S. Senate for approving the nomination of Dr. Robert Califf to be the next Commissioner of the Food and Drug Administration (FDA).
The following statement is from NHC’s Chief Executive Officer, Marc Boutin:
“In addition to serving as the gatekeeper to accessing quality treatments needed by people with chronic diseases and disabilities, the FDA serves a vital role in promoting innovative strategies to improve the research, development, and regulation of new medicines and devices. In recent years, the Agency has developed many new opportunities for people with chronic conditions to engage with the FDA and has begun incorporating patient perspectives in the regulation of medical products. It is critical that the new Commissioner continue this important work. The patient advocacy community sincerely thanks the Senate for approving Dr. Califf to lead the Agency and for considering his nomination in a timely fashion. He will bring to the FDA a proven track record of inclusiveness and a creative mindset.”
Founded in 1920, the NHC is the only organization that brings together all segments of the health community to provide a united voice for the more than 133 million people with chronic diseases and disabilities and their family caregivers. Made up of more than 100 national health-related organizations and businesses, the NHC's core membership includes the nation’s leading patient advocacy organizations, which control its governance and policy-making process. Other members include professional and membership associations, nonprofit organizations with an interest in health, and representatives from the pharmaceutical, generic drug, insurance, medical device, and biotechnology industries.
- NHC Letter of Support for Dr. Califf: http://www.nationalhealthcouncil.org/sites/default/files/Califf-Confirma...